You are here:

Forthcoming Submission: telotristat (Xermelo)

Indication: for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin anologue (SSA) therapy in adults inadequately controlled by SSA therapy.

Drug Details

Drug Name: telotristat (Xermelo)
Drug Manufacturer: Ipsen Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018